

2019 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Dallas, TX – March 2, 2019

Conference Location	Embassy Suites Dallas Park Central 13131 North Central Expressway Dallas, Texas	Phone: (972) 234-3300 https://embassysuites3.hilton.com/en/hotels/tex-embassy-suites-by-hilton-dallas-park-central-area-DALTXES/index.html
----------------------------	--	--

Parking at the Conference Parking for all participants is complimentary

Driving Directions

From I-635 East or West:

- Take Hwy 75 North to Exit #22 Spring Valley, make a U-Turn and follow the service road about 1.5 miles to the hotel entrance.
- Hotel will be located on the right.

From Hwy 75 (Traveling South)

- Exit #22A Frontage Road and follow the service road to the hotel entrance.
- Hotel will be located on the right

Seminar Agenda and Syllabus Information

Registration and breakfast begin at **7:30 a.m.** in the **Mesquite Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

<i>7:30 am</i>	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00am	Opening Comments and Pre-Test
8:20 am	<p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease <p>Liver Transplantation</p> <ul style="list-style-type: none"> • Listing Criteria and MELD Exceptions <p>Case Study 1 – Cirrhosis and Encephalopathy</p>
9:20 am	<p>Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
<i>10:00 am</i>	<i>Break & View Exhibits</i>
10:15 am	<p>Hepatocellular Carcinoma: New Systemic Treatment Options</p> <ul style="list-style-type: none"> • Currently FDA Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC <p>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</p>

11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:25 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Lunch & View Exhibits
1:00 pm	The Best Use of Non-Invasive Imaging for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis and Evaluation • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
2:15 pm	Break & View Exhibits
2:25 pm	NASH Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Drugs in Clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:25 pm	Post-test and Wrap-Up <ul style="list-style-type: none"> • Adjourn at 3:40pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your
Seminar
Faculty**



STEPHEN HARRISON, MD

Dr. Stephen A. Harrison is the Medical Director of Pinnacle Clinical Research. He earned his medical degree from the University Of Mississippi School Of Medicine. He completed his Internal Medicine residency and Gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.

He is a past Associate Editor for Hepatology and is currently an Associate Editor for Alimentary Pharmacology and Therapeutics. He is a peer-reviewer for over 20 medical journals and internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 150 peer reviewed publications in these fields. Dr. Harrison most recently served as a Colonel in the United States Army, retiring after 20 years of dedicated service.



JACQUELINE O'LEARY, MD, MPH

Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received and MD with thesis for work in cellular and molecular biology.

Following her internal medicine residency at UT Southwestern in Dallas.

Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research there at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health. These accomplishments make her uniquely poised to translate research findings into clinical care.

She has focused her clinical research in transplant hepatology, viral hepatitis, and Acute-on-Chronic Liver Failure and is currently the Chief of Hepatology at the Dallas VA Medical Center.



JORDAN MAYBERRY, MPAS, PA-C

Jordan Mayberry, MPAS, PA-C is a Hepatology physician assistant in the Department of Digestive and Liver Disease at UT Southwestern Medical Center in Dallas, Texas. She graduated from UT Southwestern Medical Center in 2012 with a masters in Physician Assistant Studies.

Following graduation she completed the AASLD NP/PA Fellowship program in 2013. Ms. Mayberry has worked in liver disease for over 6 years.
